Colospan Receives FDA Breakthrough Device Designation for Its Intraluminal Bypass Device

Colospan, which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved a product line extension to its Intraluminal Bypass Device as part of the company’s investigational device exemption (IDE) application. The line extension offers surgeons size selection for Colospan’s flagship CG-100 product, a device designed to reduce diverting stoma rates in patients undergoing a gastrointestinal resection procedure.